AI Science Tracker

AcRanker-guided discovery of AcrIIA20 and AcrIIA21 anti-CRISPR proteins

University of California, Berkeley; Monash University; University of Melbourne · 21 May 2020 · biology

Discovery

AcRanker-guided discovery of AcrIIA20 and AcrIIA21 anti-CRISPR proteins

AcRanker, an XGBoost ranking model using amino-acid sequence features, ranked proteins from prophage regions in self-targeting Streptococcus genomes. Experimental testing identified two previously unknown type II-A anti-CRISPRs: AcrIIA20 (ML1), which strongly inhibited Streptococcus iniae Cas9 and weakly inhibited S. pyogenes Cas9, and AcrIIA21 (ML8), which inhibited S. pyogenes, S. aureus and S. iniae Cas9 with lower potency.

Technology: AcRanker, an XGBoost pairwise ranking model trained on amino-acid composition and grouped di- and tri-mer features

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Experimental testing identified two previously unknown type II-A anti-CRISPRs: AcrIIA20 (ML1), which strongly inhibited Streptococcus iniae Cas9 and weakly inhibited S. pyogenes Cas9, and AcrIIA21 (ML8), which inhibited S. pyogenes, S. aureus and S. iniae Cas9 with lower potency.
  • Still unknown: The authors selected 10 candidates for follow-up, successfully purified nine and reported three validated candidates across their experiments, including ML3/AcrIIA12, which had also been identified separately as an LmoCas9 inhibitor during the study. AcrIIA20 and AcrIIA21 were roughly tenfold less potent against SpyCas9 than the established AcrIIA4 control; tested potency and host range are assay-specific. The 2025 Evo paper reports distinct generated proteins EvoAcr1–5 and separate assays; shared anti-CRISPR function does not make these identical discoveries.
  • AI role: The model ranked candidate proteins from predicted prophage regions for anti-CRISPR likelihood; the researchers selected candidates from those rankings and biochemically tested them. It directly prioritized the proteins later named AcrIIA20 and AcrIIA21, whose Cas9 inhibition was measured in vitro.

Evidence sources: https://academic.oup.com/nar/article/48/9/4698/5819938

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 125 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.